ArticleMicroorganisms2025
The Molecular Epidemiology of Hepatitis B Virus and Its Resistance-Associated Mutations in the Polymerase Gene in the Americas.
Article in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hepatitis B virus (HBV) is a DNA virus of major public health concern whose error-prone polymerase has driven the emergence of ten distinct genotypes and a multitude of resistance-associated mutations (RAMs). Herein, we conducted a retrospective observational study analyzing 8152 hepatitis B virus (HBV) sequences from 27 regions across the Americas, retrieved from GenBank, to construct a database and examine associations among HBV genotypes/subtypes, geographic distribution, resistance-associated mutations (RAMs), and resistance to nucleos(t)ide analogs (NAs) used in the treatment of chronic infection. Following phylogenetic analysis, mutations at clinically relevant sites in the reverse transcriptase domain were identified and classified by resistance to NAs. Genotypes A (21.1% A2 and 14.7% A1) and D predominated across the retrieved database, whereas genotypes E, G, H, and I each accounted for fewer than 3% of the sequences. Among the sequences in the database, 10.6% harbored RAMs, with genotypes G, A, and H predominating in this category. The most frequently observed RAM was L180M + M204V/I, which is associated with resistance to LMV, ETV, and TBV, whereas resistance to ADV and TDF remained rare. Genotypes G and A2 were significantly associated with a higher likelihood of harboring multiple RAMs (as evaluated by logistic regression), along with an increased risk of resistance to LMV, ETV, and TBV; the opposite was true for subtype A1. Notably, genotypes H and B5 were associated with an elevated risk of TDF resistance. A comprehensive understanding of RAMs and circulating genotypes in the Americas is essential for identifying high-risk populations and establishing geographically targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.